Medtech Nervous About 'Sharing' Organizations Touted In US FDA Cyber Guidance
This article was originally published in SRA
Executive Summary
Medtech industry lobbyists say US Food and Drug Administration's recommendation for companies to join information sharing and analysis organizations (ISAOs) when dealing with cybersecurity issues is ambiguous and could have serious legal ramifications. Besides asking for clarification about what constitutes an ISAO, industry groups are calling for the agency to give companies more leeway to deal with potential cybersecurity vulnerabilities.
You may also be interested in...
US FDA Pushes Further On Cybersecurity Efforts Despite Limited Resources
US FDA unveiled multiple cybersecurity-related initiatives, including two memoranda of understandings to launch information sharing organizations and playbook for health-care delivery organizations. The agency is continuing a multi-front attack in the area, despite limited resources.
'Sharing' Organizations Stay In Final Post-Market Cybersecurity Guidance
Despite pushback from industry groups on the use of information-sharing and analysis organizations (ISAOs), US FDA has kept the language the same in its final post-market cybersecurity guidance, but has removed the term "essential clinical performance."
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”